Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyHAP A1-PI Augmentation Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentHealth Alliance Plan (HAP)Policy N/A

    Prior Authorization Criteria — A1-PI Augmentation Products and Selected Specialty Agents

    Customize your policy alerts

    Sign up for all Health Alliance Plan (HAP) policy alerts

    Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage guidance for A1-PI augmentation products (ARALAST NP, GLASSIA, PROLASTIN-C, ZEMAIRA) including required documentation, prescriber restrictions, and coverage duration for Health Alliance Plan members.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyPrior Authorization Criteria — A1-PI Augmentation Products and Selected Specialty Agents
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required labs (A1-PI phenotype and baseline level), weight, and ensure prescription is written by a pulmonologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4A1-PI augmentation products listed
    Requiredprior authorization required
    1 yearcoverage duration
    pulmonologistprescriber restriction

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Diagnosis + phenotyperequired medical information

    Coverage Criteria and Product-Specific Authorization Rules

    inv-01: Initial coverage criteria

    Covered when ALL of the following are met

    A1-PI augmentation coverage criteria: Member has diagnosis of severe congenital A1-PI deficiency with clinically evident emphysema; required documentation includes patient weight, A1-PI phenotype, and baseline A1-PI level; prescription is written by a pulmonologist; prior authorization obtained

    Coverage duration limited to 1 year

    inv-02: AKEEGA — Initial Authorization

    AKEEGA — Approve when ALL of the following are met:

    AKEEGA criteria: Diagnosis: metastatic castration-resistant prostate cancer with deleterious or suspected deleterious BRCA mutation; beneficiary is of appropriate age per FDA labeling; prescriber is an Oncologist or Urologist; prior authorization obtained

    Coverage duration: 5 years

    inv-03: ALK TKIs — Initial Authorization

    ALK-positive tyrosine kinase inhibitors — Approve when ALL of the following are met:

    ALK TKI group: Diagnosis documented for the indicated ALK-positive malignancy; prescribed by an oncologist; beneficiary age appropriate per FDA labeling when specified; prior authorization obtained

    Coverage duration: 5 years

    inv-04: ALUNBRIG — Initial/Continuation Therapy

    ALUNBRIG — Approve when ALL of the following are met:

    ALUNBRIG criteria: Diagnosis: metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an approved test; prescribed by or in consultation with an oncologist; prior authorization obtained

    Coverage duration: 5 years; may approve continuation of prior therapy

    inv-05: FIRDAPSE — Initial Authorization

    FIRDAPSE (amifampridine) — Approve when ALL of the following are met:

    FIRDAPSE criteria: Documented diagnosis of Lambert-Eaton myasthenic syndrome confirmed by electrodiagnostic studies including repetitive nerve stimulation and anti-P/Q-type VGCC antibody testing; prescription written by a neurologist; prior authorization obtained

    Coverage duration: 1 year

    inv-06: Aprepitant — Initial Authorization

    Aprepitant — Approve when ALL of the following are met:

    Aprepitant criteria: Used with highly or moderately emetogenic chemotherapy with documentation of the chemotherapy regimen (drug, dose, frequency); if used for PONV, provide rationale why preferred agents (e.g., ondansetron) are not appropriate; prior authorization obtained

    Coverage duration: 6 months

    inv-07: Antidepressants — Initial Authorization

    Selected Antidepressants — Approve when ALL of the following are met:

    Antidepressants criteria: Diagnosis (e.g., major depressive disorder) documented; prior therapies tried and failed documented — for MDD a trial of two generic antidepressants from different classes is required (examples provided in policy); prior authorization obtained

    Coverage duration: 5 years

    inv-08: Antipsychotics — Initial Authorization

    Selected Antipsychotics — Approve when ALL of the following are met:

    Antipsychotics criteria: Diagnosis and treatment history documented; for bipolar disorder or schizophrenia, treatment failure with two atypical antipsychotics (or documented rationale why alternatives are unsuitable); for MDD augmentation, required prior trials documented or rationale provided; prior authorization obtained

    Coverage duration: 3 years

    inv-09: Sample: BALVERSA

    Examples of product-specific PA requirements (selection from this section):

    BALVERSA requirements: Diagnosis documented; prescription written by an oncologist; prior authorization obtained

    Coverage duration: 5 years; exclusion criteria: N/A

    inv-10: BENLYSTA SUBCUTANEOUS - Initial Therapy

    Covered when ALL of the following are met:

    BENLYSTA SUBCUTANEOUS initial criteria: Diagnosis documented with appropriate autoantibody testing; documentation of prior treatments and responses; beneficiary age appropriate per FDA labeling; prescription written by a rheumatologist or nephrologist; prior authorization obtained

    Coverage duration: 3 years; exclusions include severe active lupus nephritis, active CNS lupus, and concomitant use with other biologic drugs

    BENLYSTA prerequisite therapy: Failed to demonstrate adequate response to TWO standard therapies at recommended doses (e.g., corticosteroids, antimalarials, NSAIDs, and/or immunosuppressants)2 therapies

    inv-11: BONSITY - Initial Therapy

    Covered when ALL of the following are met:

    BONSITY initial criteria: Diagnosis and fracture history documented; prior therapy and response documented including a trial of an oral bisphosphonate (or parenteral bisphosphonate if GI intolerant); required pretreatment testing performed (DXA if not within 2 years; serum calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25-hydroxyvitamin D, and 24-hour urine calcium/creatinine or fasting calcium/creatinine ratio); prior authorization obtained

    Coverage duration: 2 years; not approved in combination with other osteoporosis agents (PTH/PTHrP analogs)

    inv-12: BOSULIF - Initial and Continuation

    Covered when the following documented:

    BOSULIF initial/continuation: Diagnosis and prior therapy results documented; for continuation, documentation of prior response to bosutinib and recent CBC and LFT results; prior authorization obtained

    inv-13: CORLANOR - Heart failure coverage criteria

    Covered when ALL of the following are met for CORLANOR heart failure indication

    CORLANOR heart failure criteria: Ejection fraction less than or equal to 35% AND heart rate greater than or equal to 70 beats per minute AND in sinus rhythm AND on a maximally tolerated beta-blocker or has a contraindication to beta-blocker; prescribed by a cardiologist; prior authorization obtainedEF <= 35%; HR >= 70 bpm

    Coverage duration: 12 months

    inv-14: COSENTYX - Indication-specific coverage criteria

    Covered when ALL of the following are met for COSENTYX (disease-specific requirements summarized)

    COSENTYX general requirements: Diagnosis documented; prior treatments tried and reasons for failure documented; baseline and ongoing TB monitoring as required; prescriber is a rheumatologist or dermatologist; prior authorization obtained

    Coverage duration: 1 year; must not be used in combination with other biologic drugs or JAK inhibitors

    COSENTYX arthritis prior therapy: Trial of or contraindication to one non-biologic DMARD (e.g., methotrexate, hydroxychloroquine, sulfasalazine, azathioprine)

    Patients who have already tried a biologic are not required to 'step back'

    Plaque psoriasis prior therapy: Trial and failure (intolerance or lack of improvement) of cyclosporine and methotrexate for at least 3 months3 months

    Every two‑week dosing requires demonstration of failure of every four‑week dosing

    inv-15: Cyclobenzaprine — Covered with criteria

    Cyclobenzaprine

    cyclobenzaprine PA criteria: Medical records documenting the diagnosis; patients aged <65 years are approved; patients aged ≥65 years must meet additional criteria; prior authorization obtained

    Coverage duration: 1 year

    inv-16: CYSTADROPS — Covered with criteria

    CYSTADROPS

    CYSTADROPS PA criteria: Diagnosis documented; beneficiary age appropriate per FDA labeling; prescribing limited to an ophthalmologist or corneal specialist; documentation of corneal cystine crystals required; prior authorization obtained

    Coverage duration not specified in excerpt

    inv-17: DAURISMO — Covered with criteria

    DAURISMO

    DAURISMO PA criteria: Diagnosis documented; prescription must be written by an oncologist or hematologist; prior authorization obtained

    Coverage duration: up to 5 years

    inv-18: Demser — Covered with criteria

    Demser (metyrosine)

    Demser PA criteria: Diagnosis documented and documentation whether the patient is a candidate for surgery; prior authorization obtained

    Coverage duration: 1 year

    inv-19: Diabetic supplies — Covered with criteria

    Diabetic supplies

    Diabetic supplies PA criteria: Prescriber confirmation that the requested supply is for use directly associated with insulin delivery to the patient; prior authorization obtained

    Coverage duration: 1 year; applies to listed supply items

    inv-20: Diacomit — Covered with criteria (with noted exclusion)

    Diacomit

    Diacomit PA criteria: Prior authorization required; note that there is no clinical data to support use of Diacomit alone to treat Dravet syndrome (exclusion noted); required medical information per policy

    inv-21: Fidaxomicin — Initial Authorization

    Fidaxomicin (DIFICID) coverage when the following are met:

    Fidaxomicin criteria: Diagnosis of Clostridium difficile documented AND prescribed by or in consultation with an infectious disease specialist; prior authorization obtained

    Coverage duration: 1 month

    inv-22: DOPTELET — Initial Authorization

    DOPTELET coverage when the following are met:

    DOPTELET criteria: Documentation of diagnosis and platelet count AND prescribed by an appropriate specialist (e.g., hematologist, oncologist, gastroenterologist); prior authorization obtained

    Coverage duration: 1 month for chronic liver disease; 6 months for chronic immune thrombocytopenia; CLD-associated use requires scheduled pre-planned procedure documentation

    inv-23: DUVYZAT — Initial Authorization

    DUVYZAT coverage when the following are met:

    DUVYZAT criteria: Genetically confirmed diagnosis of Duchenne muscular dystrophy AND baseline function tests documented AND prescribed by or in consultation with a specialist experienced in DMD; prior authorization obtained

    Patient ambulatory at initiation; coverage duration: 1 year

    inv-24: Dronabinol — Initial Authorization

    Dronabinol coverage when the following are met:

    Dronabinol criteria: Documentation of diagnosis, previous treatments and outcomes; for cancer-related weight loss must have treatment failure or intolerance to megestrol; prior authorization obtained

    Coverage duration: 1 year; not covered for treatment of pain

    inv-25: Dupixent — Indication-specific Criteria

    Dupixent coverage when ALL of the following are met:

    Dupixent general criteria: Diagnosis appropriate to the indication AND prescriber is an allergist, immunologist, pulmonologist, otolaryngologist, dermatologist, or gastroenterologist AND indication-specific documentation provided (e.g., baseline eosinophil count ≥150 cells/mcL for asthma; mucin/culture for AFRS) AND prerequisite therapy trials per indication documented; prior authorization obtainedeosinophils >=150 cells/mcL for asthma indication

    Coverage duration: 1 year; must not be used in combination with other biologic drugs

    inv-26: Enbrel — Indication-specific Criteria

    Enbrel coverage when ALL of the following are met:

    Enbrel criteria: Diagnosis documented with concurrent medications and previous therapies tried per indication; prescribed by appropriate specialist as indicated; prior authorization obtained

    Must not be used in combination with other biologic drugs or JAK inhibitors; coverage generally 1 year; prerequisite therapy required for many indications

    inv-27: General PA and coverage criteria

    Covered when ALL of the following are met (as applicable per product):

    General prerequisites: Documentation of diagnosis, prior therapies tried or intolerances, and concurrent medications as required by product-specific criteria; prior authorization obtained

    See product-specific entries for exact agents, tests, and durations

    Prescriber and age restrictions: Beneficiary must be of appropriate age per FDA labeling; certain products require prescription by or in consultation with specialists (e.g., neurologist for Epidiolex, rheumatologist/dermatologist for some biologics); prior authorization obtained

    Exceptions may apply for pediatric patients as noted

    Exclusions: Products must not be used in combination with other biologic drugs or JAK inhibitors where explicitly listed; other exclusions apply per product

    Requests that violate exclusions should be denied

    inv-28: Epidiolex prior therapy requirements

    Covered for specific seizure syndromes when evidence of prior trials is provided:

    Lennox-Gastaut Syndrome: Documentation of prior use of valproate and lamotrigine with outcomes (treatment failure or intolerance); prior authorization obtained

    Epidiolex coverage

    Dravet Syndrome: Documentation of prior use of valproate and topiramate with outcomes (treatment failure or intolerance); prior authorization obtained

    Epidiolex coverage

    Refractory seizures: Documentation of prior use of two different anticonvulsant drugs from different pharmacologic classes with outcomes (intolerance or treatment failure); prior authorization obtained

    Epidiolex coverage

    inv-29: Ergotamine derivatives coverage criteria

    Covered for migraine when ALL of the following are met:

    Triptan trial: Trial and failure of two different triptans covered on the formulary (one oral tablet and one other formulation — nasal spray or injection) unless contraindicated; prior treatments and responses documented; prescriber is a headache specialist, pain management specialist, or neurologist; prior authorization obtained

    Coverage duration: 1 year

    inv-30: Dihydroergotamine nasal (for migraine)

    Covered when ALL of the following are met

    Migraine PA requirements (dihydroergotamine nasal): Diagnosis provided; prior treatments and responses documented; beneficiary age appropriate per FDA labeling; prescriber is a headache specialist, pain management specialist, or neurologist; trial and failure of two different triptans (one oral tablet and one other formulation) unless contraindicated; prior authorization obtained

    Coverage duration: 1 year

    inv-31: ERIVEDGE

    Covered when ALL of the following are met

    ERIVEDGE PA requirements: Diagnosis provided; patient is not a candidate for surgery or radiation; prescriber must be an oncologist or dermatologist; prior authorization obtained

    Coverage duration: 5 years

    inv-32: ERLEADA (enzalutamide) oral tablets

    Covered when ALL of the following are met

    ERLEADA PA requirements: Diagnosis and prior therapies/outcomes documented (including fall risk and seizure history as applicable); prescriber must be an oncologist or urologist; prior authorization obtained

    Coverage duration: 1 year; for certain prostate cancer indications require failure/intolerance/contraindication to abiraterone

    inv-33: Erythropoiesis Stimulating Agents (Aranesp, Epogen)

    Covered when ALL of the following are met

    ESA initial requirements: Pre-treatment hemoglobin < 10 g/dL AND adequate iron stores documented (ferritin >100 mcg/L or transferrin saturation >20%) AND other causes of anemia ruled out; prescriber specialty appropriate to indication; prior authorization obtainedpre-treatment Hb < 10 g/dL; ferritin >100 mcg/L or TSAT >20%

    Exclusions: uncontrolled hypertension; pure red cell aplasia that begins after ESA treatment; coverage duration: 1 year

    inv-34: EXXUA (vilazodone ER) for MDD

    Covered when ALL of the following are met

    EXXUA PA requirements: Diagnosis of major depressive disorder documented; prior therapies tried and failed including two generic antidepressants with one being vilazodone; prior authorization obtained

    Coverage duration: 5 years

    inv-35: FASENRA (benralizumab)

    Covered when ALL of the following are met

    FASENRA PA requirements: Diagnosis of severe asthma AND currently receiving inhaled and/or oral corticosteroid treatment AND baseline eosinophil count >= 150 cells/mcL within the prior 12 months AND required baseline spirometry and asthma history provided; prescriber is a pulmonologist, immunologist, allergist, or rheumatologist; prior authorization obtainedbaseline eosinophils >=150 cells/mcL

    Must not be used in combination with other biologic drugs; coverage duration: 1 year

    inv-36: FILSUVEZ and FINTEPLA

    Covered when ALL of the following are met

    FILSUVEZ/FINTEPLA PA requirements: Diagnosis provided; beneficiary age appropriate per FDA labeling; prior authorization obtained

    Coverage/other criteria not specified in excerpt

    inv-37: FORTEO (teriparatide)

    Covered when ALL of the following are met

    FORTEO PA requirements: Diagnosis, fracture history, prior therapy and response documented; required pretreatment testing performed (DXA if not in past 2 years; serum calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25-hydroxyvitamin D; 24-hour urine calcium and creatinine or fasting specimen); prescriber is an endocrinologist; prior authorization obtained

    Coverage duration: 2 years; requires trial and failure on an oral bisphosphonate (or parenteral if GI intolerant) AND trial and failure on denosumab; not to be combined with other PTH/PTHrP analogs

    inv-38: Forteo Initial Therapy

    Forteo (teriparatide) covered when ALL of the following are met:

    Forteo initial criteria: Provider documents diagnosis, fracture history, prior therapy and response; required pretreatment testing as specified; trial and failure on oral bisphosphonate (or parenteral if GI intolerant) AND trial and failure on denosumab; prescriber is an endocrinologist; prior authorization obtained

    Coverage duration: 2 years; failure defined as intolerance, decreased BMD vs prior DEXA, or new fracture

    inv-39: Fotivda Criteria

    Fotivda (tivozanib) covered when ALL of the following are met:

    Fotivda criteria: Diagnosis, prior therapy used and result documented; if continuation, documentation of response to tivozanib; prior authorization obtained

    Prescriber and coverage details per PA

    inv-40: Fruzaqla Initial Therapy

    Fruzaqla covered when ALL of the following are met:

    Fruzaqla criteria: Diagnosis of metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy AND an anti-VEGF AND anti-EGFR if RAS wild-type when appropriate; prescribed by or in consultation with a hematologist/oncologist; prior authorization obtained

    Coverage duration: 5 years

    inv-41: Fycompa Criteria

    Fycompa (perampanel) covered when ALL of the following are met:

    Fycompa criteria: Diagnosis documented; prescription by a neurologist; monitoring for serious psychiatric and/or behavioral reactions with clinical notes as applicable; prior authorization obtained

    Coverage duration: 5 years

    inv-42: Gabarone Criteria

    Gabarone covered when ALL of the following are met:

    Gabarone criteria: Beneficiary age appropriate per FDA labeling; must have intolerance, contraindication, or medical reason precluding gabapentin; prior authorization obtained

    Indications limited to some FDA‑approved uses

    inv-43: GATTEX Criteria

    GATTEX covered when ALL of the following are met:

    GATTEX criteria: Diagnosis and documentation of other therapies tried and responses; for adults, colonoscopy of entire colon with removal of polyps documented prior to initiation; prescriber is a gastroenterologist; prior authorization obtained

    Discontinue therapy if intestinal malignancy occurs; coverage duration: 3 years

    inv-44: Gaucher's Disease Treatment Criteria

    Gaucher's disease treatments covered when ALL of the following are met:

    Cerdelga/miglustat criteria: Diagnosis documented; for miglustat provide rationale why enzyme replacement therapy is not appropriate; prescriber is a geneticist, hematologist, hepatologist or metabolic specialist; prior authorization obtained

    Not approved for Type II or Type III Gaucher's disease; coverage duration: 3 years

    inv-45: Gavreto Criteria

    Gavreto covered when ALL of the following are met:

    Gavreto criteria: Diagnosis documented; beneficiary age appropriate per FDA labeling; prescription must be written by an oncologist or pulmonologist; diagnosis of NSCLC or thyroid cancer verified by an FDA‑approved diagnostic test for RET fusion; prior authorization obtained

    Coverage duration: 5 years

    inv-46: GAVRETO

    GAVRETO

    GAVRETO approval requirements: Diagnosis; beneficiary is of appropriate age per FDA; prescription must be written by an oncologist or pulmonologist; diagnosis verification by an FDA‑approved diagnostic test for RET fusion mutations; prior authorization obtained

    Coverage duration: 5 years

    inv-47: GILOTRIF

    GILOTRIF

    GILOTRIF approval requirements: Diagnosis documented; prescription must be written by an oncologist; prior authorization obtained

    Coverage duration: 5 years

    inv-48: GLEOSTINE

    GLEOSTINE

    GLEOSTINE approval requirements: Diagnosis documented; beneficiary appropriate age per FDA labeling; prior authorization obtained

    Coverage duration: 5 years

    inv-49: TRULICITY

    TRULICITY

    TRULICITY approval requirements: Documented diagnosis of Type 2 diabetes and submitted A1C from the past 6 months; not for weight loss; prior authorization obtained

    Coverage duration: 1 year; prerequisite therapy required as specified

    inv-50: GOMEKLI

    GOMEKLI

    GOMEKLI approval requirements: Documentation of diagnosis; prescribed by an oncologist or neurologist; prior authorization obtained

    Coverage duration: 5 years

    inv-51: Growth hormone

    Growth hormone (Norditropin Flexpro)

    Growth hormone approval requirements: Diagnosis documented; height and weight and history of growth measurements provided; confirmation of growth hormone deficiency by appropriate testing; prescription by an endocrinologist or nephrologist; prior authorization obtained

    Coverage duration: 3 years; exclusion: presence of contraindications to therapy

    inv-52: General PA and prerequisite therapy criteria (excerpt)

    Covered when ALL of the following are met (product-specific):

    General prerequisites: Prescriber and age must be appropriate per FDA labeling; required medical information and prior therapy trials (when specified) must be submitted; prior authorization obtained

    See specific product nodes for exact requirements

    Product-specific prerequisite therapy examples: Examples: RA — trial of one conventional synthetic DMARD ≥3 months; COSENTYX arthritis — trial or contraindication to one non-biologic DMARD; Triptan trial for migraine therapies — trial and failure of two different triptans; other product-specific trials as listed

    Prerequisite therapy applies when specified per product

    Exclusions: Certain combination therapies are excluded (e.g., dual biologic/JAKi use, dual HAE prophylaxis formulations); requests violating exclusions should be denied

    See product-specific exclusion fields

    inv-53: HUMULIN R U-500 authorization

    General PA attributes for HUMULIN R U-500

    HUMULIN R U-500 PA: Prior authorization criteria present; beneficiary age appropriate per FDA labeling; prior authorization obtained

    Coverage duration per product entry

    inv-54: HYRNUO authorization

    General PA attributes for HYRNUO

    HYRNUO PA: Prior authorization criteria present; beneficiary age appropriate per FDA labeling; prior authorization obtained

    Coverage duration per product entry

    inv-55: Ibrance authorization

    Ibrance prior authorization criteria

    Ibrance PA: Required documentation: diagnosis and previous therapies tried; prescriber must be an oncologist; prior authorization obtained

    Coverage duration: 1 year; trial of Kisqali or Verzenio required prior to approval unless specified exceptions (PIK3CA‑mutated cases)

    inv-56: Idhifa authorization

    Idhifa prior authorization criteria

    Idhifa PA: Required documentation: diagnosis; prescribed by or in consultation with a hematologist/oncologist; prior authorization obtained

    Coverage duration: 5 years

    inv-57: Imbruvica authorization

    Imbruvica prior authorization criteria

    Imbruvica PA: Required documentation: diagnosis; prescription must be by an oncologist, hematologist, or transplant specialist; prior authorization obtained

    Coverage duration: 1 year

    inv-58: Product-specific PA criteria

    Each product is subject to its own PA criteria; common elements include required medical information, prescriber restrictions, coverage duration, indications, and prerequisite therapy.

    IMKELDI: PA Criteria: required per product; prescriber and age appropriate per FDA; prior authorization obtained

    Coverage duration commonly 5 years where specified

    IMPAVIDO: PA Criteria: required per product; required medical information: leishmaniasis diagnosis; prior authorization obtained

    Prescriber specialist required as noted

    INBRIJA: PA Criteria: diagnosis and prior therapy documented; required trial and failure of both carbidopa/levodopa IR and ER and at least one other Parkinson's drug; prior authorization obtained

    Coverage duration: 3 years

    INCRELEX:

    This portion of the policy does not list any explicit exclusion conditions for the A1‑PI augmentation products (ARALAST NP, GLASSIA, PROLASTIN‑C, ZEMAIRA). The product entries show required documentation — including diagnosis of severe congenital A1‑PI deficiency with clinically evident emphysema, patient weight, A1‑PI phenotype, and baseline A1‑PI level — plus a prescriber restriction that the prescription must be written by a pulmonologist and a coverage duration of 1 year, but no additional exclusion criteria are specified in this excerpt.

    The excerpts in this segment commonly show product-level entries where the field for exclusion criteria is recorded as N/A. For example, the AKEEGA entry explicitly lists Exclusion Criteria: N/A while specifying required diagnosis, prescriber specialty, age appropriateness, and a coverage duration of 5 years.

    Multiple product entries in this segment either leave the Exclusion Criteria field blank or mark it as N/A. Examples include ARCALYST, ARIKAYCE, ATTRUBY, AUGTYRO, AVMAPKI‑FAKZYNJA, AYVAKIT, and BALVERSA — each lists required documentation, prescriber restrictions, and coverage duration but shows no additional exclusion conditions in the provided excerpts.

    Coding for Affected Products

    A1-PI augmentation productsmixed
    ARALAST NPProduct affected
    GLASSIAProduct affected
    PROLASTIN-C INTRAVENOUS SOLUTIONProduct affected
    ZEMAIRAProduct affected
    Prior authorization notemixed
    No codes listed
    ALK TKIs (listed products)mixed
    ALECENSAproduct name listed
    XALKORIproduct name listed (oral capsule/pellet)
    ZYKADIAproduct name listed
    ALUNBRIGmixed
    ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MGproduct and strengths listed
    ALUNBRIG ORAL TABLETS,DOSE PACKproduct listing
    AMIFAMPRIDINE / FIRDAPSEmixed
    FIRDAPSEamifampridine product listed
    AKEEGAmixed
    AKEEGAproduct listed
    APREPITANTmixed
    aprepitantproduct listed
    ANALEPTICmixed
    armodafinilproduct listed
    modafinil 100 mg, 200 mgproduct and strengths listed
    Selected Antidepressantsmixed
    AUVELITYproduct listed
    FETZIMAproduct listed
    TRINTELLIXproduct listed
    vilazodoneproduct listed
    Selected Antipsychoticsmixed
    asenapine maleateproduct listed
    CAPLYTAproduct listed
    REXULTIproduct listed
    Products Affected (cyclobenzaprine)mixed
    cyclobenzaprine oral tablet 10 mgproduct listing from policy
    cyclobenzaprine oral tablet 5 mgproduct listing from policy
    Products Affected (CYSTADROPS)mixed
    CYSTADROPSproduct listing from policy
    Products Affected (DAURISMO)mixed
    DAURISMO ORAL TABLET 100 MGproduct listing from policy
    DAURISMO ORAL TABLET 25 MGproduct listing from policy
    Products Affected (Demser/metyrosine)mixed
    metyrosineDemser product listing from policy
    Products Affected (Diabetic supplies)mixed
    alcohol padsdiabetic supply product
    GAUZE PADS 2 X 2diabetic supply product
    INSULIN PEN NEEDLEdiabetic supply product
    INSULIN SYRINGE (DISP) U-100 0.3 ML 29 GAUGEdiabetic supply product
    INSULIN SYRINGE (DISP) 1 ML 29 GAUGE X 1/2"diabetic supply product
    INSULIN SYRINGE (DISP) 1/2 ML 28 GAUGEdiabetic supply product
    NEEDLES, INSULIN DISP.,SAFETYdiabetic supply product
    Products Affected (Diacomit)mixed
    DIACOMITproduct listing from policy
    Products Affectedmixed
    HUMULIN R U-500 (CONC) INSULINProduct affected
    HUMULIN R U-500 (CONC) KWIKPENProduct affected
    Products Affectedmixed
    HYRNUOProduct affected
    Products Affectedmixed
    IBRANCE ORAL CAPSULE 125 MGProduct affected
    IBRANCE ORAL TABLETProduct affected
    Products Affectedmixed
    IBTROZIProduct affected
    Products Affectedmixed
    ICLUSIGProduct affected
    Products Affectedmixed
    IDHIFAProduct affected
    Products Affectedmixed
    IMBRUVICA ORAL CAPSULE 140 MGProduct affected
    IMBRUVICA ORAL SUSPENSIONProduct affected
    IMBRUVICA ORAL TABLETProduct affected
    Products Affectedmixed
    IMKELDIProduct affected
    inv-109: Baseline eosinophil count
    Threshold>= 150 cells/mcL (baseline within previous 12 months)
    Applies toAsthma indication for Dupixent and similar IL-targeted biologics
    Documentation window

    Prior Authorization Actions, Documentation, and Denial Risks

    Prior Authorization

    PA required for A1-PI augmentation products

    Prior authorization is required for the listed A1-PI augmentation products; submit required medical information including diagnosis of severe congenital A1-PI deficiency with clinically evident emphysema, patient weight, A1-PI phenotype, and baseline A1-PI level. Prescription must be written by a pulmonologist; coverage duration is 1 year.

    • Required medical information: diagnosis, weight, phenotype, baseline A1-PI level
    • Prescriber restriction: pulmonologist
    • Coverage duration: 1 year
    Prior Authorization

    AKEEGA — prior authorization and prescriber requirement

    AKEEGA requires prior authorization with documentation of diagnosis (metastatic castration‑resistant prostate cancer with deleterious or suspected deleterious BRCA mutation) and that the prescriber is an oncologist or urologist; beneficiary age must be appropriate per FDA labeling. Coverage duration: 5 years.

    • Diagnosis: metastatic castration‑resistant prostate cancer with deleterious or suspected deleterious BRCA mutation

    Background — Condition and Therapy Context

    Alpha‑1 antitrypsin (A1‑PI) deficiency is a hereditary condition that can result in early‑onset emphysema. The policy supports augmentation therapy with plasma‑derived A1‑PI products for members who have a documented diagnosis of severe congenital A1‑PI deficiency with clinically evident emphysema. Prior authorization is required and the request must include documentation of the patient’s A1‑PI phenotype and baseline A1‑PI level, current weight, and be prescribed by a pulmonologist. Coverage authorizations are limited to 1 year per the terms shown in the policy excerpt.

    Key Definitions and Required Clinical Data

    inv-268: Eligible diagnosis
    Eligible diagnosisSevere congenital A1-PI deficiency with clinically evident emphysema
    Required prescriberPrescription must be written by a pulmonologist
    Coverage duration1 year per authorization
    inv-269: Required laboratory documentation
    Required labsA1-PI phenotype and baseline A1-PI level to document deficiency
    Additional clinical infoPatient weight and diagnosis documentation
    Submission requirement
    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyPrior Authorization Criteria — A1-PI Augmentation Products and Selected Specialty Agents
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required labs (A1-PI phenotype and baseline level), weight, and ensure prescription is written by a pulmonologist.
    SourceLink
    On This Page
    Coverage Criteria and Product-Specific Authorization RulesCoding for Affected ProductsPrior Authorization Actions, Documentation, and Denial RisksBackground — Condition and Therapy ContextKey Definitions and Required Clinical Data
    Hidradenitis suppurativa prior therapy: Patient has tried one other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin)
    PA Criteria: required per product; required medical information includes IGF-1 level; prior authorization obtained
    TOBI Podhaler (Inhaled Tobramycin): PA Criteria: required per product; prescriber must be an infectious disease specialist or pulmonologist; prior authorization obtained

    Coverage duration: 1 year

    INLURIYO/INLYTA/INQOVI: PA Criteria: required per product; prior authorization obtained; prescriber and age appropriate per FDA
    Measured within the previous 12 months
    inv-110: FASENRA baseline eosinophil
    Threshold>= 150 cells/mcL (baseline within previous 12 months)
    IndicationSevere asthma for FASENRA (benralizumab)
    Required documentationBaseline eosinophil count included in required medical information
    inv-111: ESA pre-treatment hemoglobin
    ThresholdPre-treatment hemoglobin < 10 g/dL
    Applies toErythropoiesis-stimulating agents (Aranesp, Epogen)
    Additional requirementRule out other causes of anemia (per required medical information)
    inv-112: ESA adequate iron stores
    DefinitionAdequate iron stores = ferritin > 100 mcg/L or transferrin saturation > 20%
    ContextRequired prior to ESA (Aranesp, Epogen) initiation
    PurposeConfirm iron repletion before ESA therapy to optimize response
  1. Prescriber restriction: oncologist or urologist
  2. Coverage duration: 5 years
  3. Prior Authorization

    ALK TKIs — PA and prescriber restriction

    ALK tyrosine kinase inhibitors require prior authorization; submit diagnosis and ensure the prescription is written by an oncologist. Coverage duration is 5 years.

    • Products: ALECENSA, XALKORI, ZYKADIA
    • Prescriber restriction: oncologist
    • Coverage duration: 5 years
    Prior Authorization

    ALUNBRIG — ALK confirmation and PA

    ALUNBRIG requires prior authorization with documentation that metastatic NSCLC is ALK‑positive as detected by an approved test; prescription must be by or in consultation with an oncologist. Coverage duration: 5 years; continuation of prior therapy may be approved.

    • Required: ALK‑positive NSCLC confirmed by an approved test
    • Prescriber restriction: oncologist (or consult)
    • Coverage duration: 5 years; continuation may be approved
    Prior Authorization

    FIRDAPSE — diagnostic confirmation and PA

    For FIRDAPSE (amifampridine) prior authorization is required; submit electrodiagnostic studies (including repetitive nerve stimulation) and anti‑P/Q‑type VGCC antibody testing to confirm Lambert‑Eaton diagnosis. Prescription must be written by a neurologist. Coverage duration: 1 year.

    • Diagnostic confirmation: electrodiagnostic studies and anti‑P/Q‑type VGCC antibody testing
    • Prescriber restriction: neurologist
    • Coverage duration: 1 year
    Prior Authorization

    Aprepitant — chemotherapy regimen documentation required

    Aprepitant requires prior authorization when used with highly or moderately emetogenic chemotherapy; submit the chemotherapy regimen (drug, dose, frequency). For PONV use, provide rationale why preferred agents (e.g., ondansetron) are not appropriate. Coverage duration: 6 months.

    • Required documentation: chemotherapy regimen (drug, dose, frequency)
    • For PONV: rationale why preferred agents are not appropriate
    • Coverage duration: 6 months
    Prior Authorization

    Antipsychotics — PA and prior treatment documentation

    Selected antipsychotics require prior authorization with documentation of diagnosis and treatment history; for bipolar disorder or schizophrenia, document failure of two atypical antipsychotics or provide rationale. Coverage duration: 3 years.

    • Required: diagnosis and treatment history
    • Schizophrenia/bipolar: failure of two atypical antipsychotics (or rationale)
    • Coverage duration: 3 years
    Note
    Prior Authorization

    ARIKAYCE — required documentation and PA

    ARIKAYCE prior authorization requires medical records supporting the request including sputum culture confirming MAC lung disease; prescriber must be or consult with an infectious disease specialist or pulmonologist. For initial review provide documentation of failure to obtain negative sputum cultures after ≥6 months of multidrug background regimen therapy. Coverage duration: 1 year.

    • Required documentation: sputum culture supporting MAC lung disease
    • Prior therapy documentation: failure to clear sputum after ≥6 months of multidrug regimen for initial review
    • Prescriber restriction: infectious disease specialist or pulmonologist
    • Coverage duration: 1 year
    Prior Authorization

    ATTRUBY — diagnostic confirmation and PA

    ATTRUBY requires prior authorization with confirmation of diagnosis via appropriate testing; prescription must be written by a cardiologist. Coverage duration: 1 year.

    • Required documentation: confirmation of diagnosis with appropriate testing
    • Prescriber restriction: cardiologist
    • Coverage duration: 1 year
    Note
    Prior Authorization

    AUGTYRO — prior authorization

    Prior authorization is required for AUGTYRO (oral capsules); beneficiary age must be appropriate per FDA labeling and other criteria in the product entry must be met.

    • Beneficiary age per FDA labeling
    • PA required before dispensing
    Prior Authorization

    AVMAPKI‑FAKZYNJA — PA and prescriber restriction

    AVMAPKI‑FAKZYNJA requires prior authorization; the prescription must be written by an oncologist and coverage duration is 5 years.

    • Prescriber restriction: oncologist
    • Coverage duration: 5 years
    Note
    Note
    Prior Authorization

    BENLYSTA SC — PA and required documentation

    BENLYSTA SUBCUTANEOUS requires prior authorization; submit diagnosis, autoantibody testing, and prior treatments with responses. Prescription must be written by a rheumatologist or nephrologist. Coverage duration: 3 years.

    • Required documentation: diagnosis, autoantibody testing, prior treatments and responses
    • Prescriber restriction: rheumatologist or nephrologist
    • Coverage duration: 3 years
    Note
    Note
    Note
    Prior Authorization

    BRIVIACT — PA and prerequisite therapy

    BRIVIACT (brivaracetam) requires prior authorization; prerequisite therapy is noted as required and prescriber/age must align with FDA labeling.

    • Required: documentation of response to brivaracetam and prerequisite therapy
    • Prescriber/age per FDA labeling
    Prior Authorization

    BRUKINSA — prior authorization

    BRUKINSA oral tablet requires prior authorization; no prerequisite therapy is listed and prescriber/use must follow FDA labeling.

    • PA required; Prerequisite Therapy: No
    • Prescriber/age per FDA labeling
    Note
    Note
    Note
    Note
    Note
    Prior Authorization

    COBENFY — PA and step therapy requirement

    COBENFY requires prior authorization; submit diagnosis and treatment history. For schizophrenia, document failure with two atypical antipsychotics. Coverage duration: 5 years.

    • Required documentation: diagnosis and treatment history
    • Schizophrenia: failure of two atypical antipsychotics required
    • Coverage duration: 5 years
    Note
    Prior Authorization

    COMETRIQ — PA and prescriber restriction

    COMETRIQ requires prior authorization; prescription must be written by an oncologist. Coverage duration: 5 years.

    • Prescriber restriction: oncologist
    • Coverage duration: 5 years
    Prior Authorization

    COPIKTRA — PA and prescriber restriction

    COPIKTRA requires prior authorization; prescription must be written by an oncologist or hematologist. Coverage duration: 5 years.

    • Prescriber restriction: oncologist or hematologist
    • Coverage duration: 5 years
    Prior Authorization

    CORLANOR — PA and required clinical documentation

    CORLANOR prior authorization requires documentation supporting heart failure in adults: left ventricular ejection fraction ≤35%, heart rate ≥70 bpm in sinus rhythm, and that the patient is on a maximally tolerated beta‑blocker or has a contraindication to beta‑blocker. Prescription should be by a cardiologist; coverage duration: 12 months.

    • EF ≤ 35% and HR ≥ 70 bpm in sinus rhythm
    • On maximally tolerated beta‑blocker OR contraindication to beta‑blocker
    • Prescriber restriction: cardiologist
    • Coverage duration: 12 months
    Prior Authorization

    COSENTYX — PA, documentation, and combination exclusion

    COSENTYX requires prior authorization; prescriber must be a rheumatologist or dermatologist. Submit diagnosis, prior treatments and reasons for failure, and baseline/ongoing TB monitoring. Coverage duration: 1 year; must not be used in combination with other biologic drugs or JAK inhibitors.

    • Prescriber restriction: rheumatologist or dermatologist
    • Required documentation: diagnosis, prior treatments and failures, TB monitoring
    • Coverage duration: 1 year
    • Combination therapy exclusion: not used with other biologics or JAK inhibitors
    Prior Authorization

    CRESEMBA — prior authorization and prerequisite therapy

    CRESEMBA (oral) requires prior authorization; beneficiary age must be appropriate per FDA labeling and prerequisite therapy is noted as required.

    • PA required; prerequisite therapy: Yes
    • Age per FDA labeling
    Prior Authorization

    Cyclobenzaprine — PA, documentation, and age notes

    Cyclobenzaprine oral tablets (5 mg, 10 mg) require prior authorization with medical records documenting the diagnosis. Patients under age 65 are approved; patients aged 65 and older must meet additional age‑specific criteria. Coverage duration: 1 year.

    • Required documentation: medical records documenting diagnosis
    • Patients <65: approved; patients ≥65: additional criteria apply
    • Coverage duration: 1 year
    Note
    Prior Authorization

    CYSTADROPS — prescriber restriction and diagnostic documentation

    CYSTADROPS requires prior authorization; prescribing is limited to an ophthalmologist or corneal specialist and documentation of corneal cystine crystals is required before initiation.

    • Prescriber restriction: ophthalmologist or corneal specialist
    • Required clinical finding: documentation of corneal cystine crystal
    Prior Authorization

    GATTEX — PA and required documentation

    GATTEX prior authorization requires documentation of diagnosis and prior therapies and responses; for adult patients submit colonoscopy of entire colon with polyp removal before initiation. Prescriber must be a gastroenterologist; discontinue therapy if intestinal malignancy is present. Coverage duration: 3 years.

    • Required documentation: diagnosis, prior therapies and responses; adults: colonoscopy with polyp removal documented
    • Prescriber restriction: gastroenterologist
    • Exclusion: discontinue if intestinal malignancy
    • Coverage duration: 3 years
    Prior Authorization

    Demser (metyrosine) — PA and surgical candidacy documentation

    Demser (metyrosine) prior authorization requires documentation of diagnosis and whether the patient is a candidate for surgery. Coverage duration: 1 year.

    • Required documentation: diagnosis and surgical candidacy
    • Coverage duration: 1 year
    Prior Authorization

    Diabetic supplies — PA and purpose confirmation

    Diabetic supplies require prior authorization for a 1‑year duration; prescriber must confirm that the supply is requested for use directly associated with delivering insulin to the patient.

    • Prescriber confirmation required: supply is for insulin delivery
    • Coverage duration: 1 year
    Note
    Prior Authorization

    Fidaxomicin — PA and prescriber restriction

    Fidaxomicin (DIFICID) requires prior authorization for Clostridium difficile infection and must be prescribed by or in consultation with an infectious disease specialist. Coverage duration: 1 month.

    • Required documentation: diagnosis of C. difficile
    • Prescriber restriction: infectious disease specialist (or consult)
    • Coverage duration: 1 month
    Prior Authorization

    DOPTELET — PA, documentation, and prescriber restriction

    DOPTELET requires prior authorization with documentation of diagnosis and platelet count; prescribing is limited to an appropriate specialist (e.g., hematologist, oncologist, gastroenterologist). Coverage duration varies by indication (1 month for chronic liver disease; 6 months for chronic immune thrombocytopenia).

    • Required medical information: diagnosis and platelet count
    • Prescriber restriction: appropriate specialist (hematologist/oncologist/gastroenterologist)
    • Coverage duration: indication-specific (1 month CLD; 6 months ITP)
    Prior Authorization

    Dronabinol — PA, documentation, and indication limits

    Dronabinol requires prior authorization with documentation of diagnosis, previous treatments and outcomes; for cancer‑related weight loss, document failure or intolerance to megestrol. Dronabinol is not covered for treatment of pain. Coverage duration: 1 year.

    • Required documentation: diagnosis, prior treatments and outcomes
    • Cancer cachexia: failure/intolerance to megestrol required
    • Not covered for pain
    • Coverage duration: 1 year
    Prior Authorization

    Dupixent — PA, documentation, and prescriber restriction

    Dupixent requires prior authorization with indication‑specific documentation (e.g., baseline eosinophil count for asthma, mucin/culture for AFRS). Prescribing is limited to specified specialties (allergist, immunologist, pulmonologist, otolaryngologist, dermatologist, gastroenterologist). Coverage duration: 1 year; many indications require prerequisite therapy trials.

    • Required: diagnosis and indication‑specific documentation (e.g., eosinophil ≥150 cells/mcL for asthma)
    • Prescriber restriction: specified specialties (allergist, immunologist, pulmonologist, otolaryngologist, dermatologist, gastroenterologist)
    • Coverage duration: 1 year
    • Prerequisite therapy: Yes for many indications
    Note
    Note
    Note
    Prior Authorization

    Epidiolex — required prior therapy documentation

    Epidiolex prior authorization requires documentation of prior anticonvulsant trials per indication (valproate and lamotrigine for Lennox‑Gastaut; valproate and topiramate for Dravet; two different anticonvulsants from different classes for refractory seizures). Submit diagnosis, prior therapies and outcomes; prescriber must be or consult with a neurologist.

    • Lennox‑Gastaut: documentation of valproate and lamotrigine trial/outcomes
    • Dravet: documentation of valproate and topiramate trial/outcomes
    • Refractory seizures: documentation of two different anticonvulsant trials/outcomes
    • Prescriber restriction: neurologist (or consult)
    Prior Authorization

    Dihydroergotamine nasal — PA and triptan trial requirement

    Dihydroergotamine nasal requires prior authorization; prescriber must be a headache specialist, pain management specialist, or neurologist. For migraine, document trial and failure of two different triptans (one oral tablet and one other formulation) unless contraindicated. Coverage duration: 1 year.

    • Required documentation: diagnosis, prior treatments and responses
    • Triptan trial: failure of two different triptans (one oral, one other formulation) unless contraindicated
    • Prescriber restriction: headache specialist, pain management specialist, or neurologist
    • Coverage duration: 1 year
    Note
    Note
    Note
    Note
    Note
    Prior Authorization

    FILSUVEZ — PA and age requirement

    FILSUVEZ requires prior authorization; beneficiary must be of appropriate age per FDA labeling and applicable product criteria must be met as listed in the product entry.

    • PA required; age per FDA labeling
    • Follow product‑specific criteria in PA entry
    Prior Authorization

    FINTEPLA — prior authorization

    FINTEPLA requires prior authorization; beneficiary must be of appropriate age per FDA labeling and applicable product criteria must be met as listed in the product entry.

    • PA required; age per FDA labeling
    • Follow product‑specific criteria in PA entry
    Prior Authorization

    FORTEO — PA, pretreatment testing and step therapy

    FORTEO (teriparatide) prior authorization requires documentation of diagnosis, fracture history, prior therapy and response, and required pretreatment testing (DXA if not in past 2 years; serum calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25‑OH vitamin D; 24‑hour urine calcium/creatinine or fasting specimen). Prescriber must be an endocrinologist. Prior trials and failure of an oral bisphosphonate (or parenteral if GI intolerant) AND denosumab are required. Coverage duration: 2 years.

    • Required pretreatment testing: DXA, serum calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25‑OH D, 24‑hour urine calcium/creatinine (or fasting specimen)
    • Prior therapy: trial/failure of oral bisphosphonate (or parenteral if intolerant) AND trial/failure of denosumab
    • Prescriber restriction: endocrinologist
    • Coverage duration: 2 years
    Note
    Prior Authorization

    Fruzaqla — PA and prior therapy documentation

    Fruzaqla requires prior authorization with documentation of prior therapies and treatment history consistent with metastatic colorectal cancer previously treated with specified regimens; prescriber must be or consult with a hematologist/oncologist. Coverage duration: 5 years.

    • Required documentation: prior chemotherapy regimens and treatment history
    • Prescriber restriction: hematologist/oncologist
    • Coverage duration: 5 years
    Note
    Prior Authorization

    GAVRETO — PA and diagnostic confirmation

    GAVRETO requires prior authorization; submit diagnosis and verification of RET fusion mutation by an FDA‑approved diagnostic test for NSCLC or thyroid cancer. Prescription must be written by an oncologist or pulmonologist. Coverage duration: 5 years.

    • Required documentation: diagnosis and FDA‑approved diagnostic test confirming RET fusion mutation
    • Prescriber restriction: oncologist or pulmonologist
    • Coverage duration: 5 years
    Prior Authorization

    GILOTRIF — PA and prescriber restriction

    GILOTRIF requires prior authorization with documented diagnosis; prescription must be written by an oncologist. Coverage duration: 5 years.

    • Required documentation: diagnosis
    • Prescriber restriction: oncologist
    • Coverage duration: 5 years
    Note
    Note
    Note
    Note
    Note
    Note
    Prior Authorization

    Ibrance — PA, documentation and step therapy

    Ibrance prior authorization requires documentation of diagnosis and previous therapies tried; prescription must be written by an oncologist. A trial of Kisqali or Verzenio is required prior to approval unless the beneficiary has PIK3CA‑mutated HR‑positive, HER2‑negative locally advanced or metastatic breast cancer. Coverage duration: 1 year.

    • Required documentation: diagnosis and previous therapies
    • Prescriber restriction: oncologist
    • Step therapy: trial of Kisqali or Verzenio required unless PIK3CA‑mutated exception
    • Coverage duration: 1 year
    Prior Authorization

    Idhifa — PA and prescriber restriction

    Idhifa requires prior authorization with documentation of diagnosis; prescription must be by or in consultation with a hematologist/oncologist. Coverage duration: 5 years.

    • Required documentation: diagnosis
    • Prescriber restriction: hematologist/oncologist
    • Coverage duration: 5 years
    Prior Authorization

    Imbruvica — PA and prescriber restriction

    Imbruvica requires prior authorization with documentation of diagnosis; prescription must be written by an oncologist, hematologist, or transplant specialist. Coverage duration: 1 year.

    • Required documentation: diagnosis
    • Prescriber restriction: oncologist, hematologist, or transplant specialist
    • Coverage duration: 1 year
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    BONSITY — required documentation and exclusion

    For BONSITY prior authorization submit diagnosis, fracture history, prior therapy and response, and required pretreatment testing (DXA and labs). Prescriber must be an endocrinologist; BONSITY is not approved for combination therapy with other osteoporosis agents.

    • Required: diagnosis, fracture history, prior therapy and response
    • Pretreatment testing: DXA (if not in 2 years), serum calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25‑OH D, 24‑hour urine calcium/creatinine or fasting ratio
    • Prescriber restriction: endocrinologist
    • Combination therapy exclusion applies
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Prior Authorization

    Diacomit — PA and exclusion note

    Diacomit requires prior authorization; note that the policy states there is no clinical data to support use of Diacomit alone to treat Dravet syndrome (exclusion noted).

    • PA required
    • Exclusion note: Diacomit alone for Dravet syndrome lacks supporting clinical data
    Note
    Include medical records supporting diagnosis and lab results with PA request
    inv-270: Lambert-Eaton myasthenic syndrome (LEMS)
    DefinitionLambert-Eaton myasthenic syndrome (LEMS) diagnosed by electrodiagnostic studies
    Confirmatory testsRepetitive nerve stimulation and anti-P/Q-type VGCC antibody testing
    PrescriberPrescription must be written by a neurologist for FIRDAPSE PA
    inv-271: ALK-positive NSCLC
    DefinitionNon-small cell lung cancer with ALK rearrangement confirmed by an approved test
    PA requirementMust be prescribed by or in consultation with an oncologist
    Coverage duration5 years
    inv-272: Pretreatment testing for BONSITY
    Required pretreatment testsDXA if not within 2 years; serum calcium, phosphorus, creatinine, alkaline phosphatase, albumin, 25-hydroxyvitamin D; 24-hour urine calcium and creatinine (or fasting specimen)
    Clinical contextRequired before initiating BONSITY to evaluate metabolic bone status
    PrescriberPrescription must be written by an endocrinologist
    inv-273: Baseline function tests (examples)
    ExamplesTime to wheelchair assistance, required respiratory assistance/pulmonary function tests, 4SC, 6MWT, 10MWT, NSAA
    Use caseBaseline function tests for DUVYZAT supporting ambulatory status and function
    DocumentationInclude test results in PA submission (medical records)
    inv-274: Baseline eosinophil count (Dupixent/Dupixent-related)
    Threshold>= 150 cells/mcL (baseline within previous 12 months)
    IndicationAsthma indication for Dupixent (baseline eosinophil required)
    DocumentationInclude eosinophil count in required medical information for PA
    inv-275: Adequate iron stores
    DefinitionAdequate iron stores = ferritin > 100 mcg/L OR transferrin saturation > 20%
    ContextRequired prior to ESA initiation to document iron repletion
    TestingReport ferritin or transferrin saturation values with PA request
    inv-276: Baseline eosinophil requirement (FASENRA)
    Threshold>= 150 cells/mcL (baseline within previous 12 months)
    Applies toFASENRA (benralizumab) for severe asthma
    Required with PABaseline eosinophil count must be included in required medical information
    inv-277: Continuation example (INBRIJA)
    Required for ESA initiationPre-treatment hemoglobin < 10 g/dL (highlight) and adequate iron stores per defined thresholds
    Iron stores definitionFerritin >100 mcg/L or transferrin saturation >20%
    Other requirementRule out other causes of anemia before ESA therapy